MedTrace Logo

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension

NCT06264622 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-02-20

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the dose response effect on cardiovascular disease risk factors of a Black Garlic Extract in subjects with Grade I Hypertension. The main questions it aims to answer are:

* If the reduction in blood pressure (systolic and diastolic) is in a dose-response manner
* If the changes in lipid profile are in a dose-response manner

Participants will be randomly assign to a low dose (250 mg/day), high dose (600 mg/day) or placebo of a standardized Garlic Extract (ABG+/GarlACE) during 12 weeks

Conditions

Interventions

DIETARY_SUPPLEMENT

Low dose

2 tablets per day during the morning for 12 weeks.

DIETARY_SUPPLEMENT

High dose

2 tablets per day during the morning for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

2 tablets per day during the morning for 12 weeks.

Sponsors & Collaborators

  • Pharmactive Biotech Products S.L.U

    collaborator INDUSTRY

  • Universitat de Lleida

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-26
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06264622 on ClinicalTrials.gov